NDC 0093-7769-19 - Everolimus
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0093-7769
- Requested NDC
- 0093-7769-19
- Package NDCs from labels
- 0093-7769-19, 0093-7769-24
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Effective date
- 2026-06-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Everolimus - Teva Pharmaceuticals USA, Inc. | Teva Pharmaceuticals USA, Inc. | 2026-06-29 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0093-7769-19 | Everolimus | 1 in 1 BLISTER PACK | TABLET | 1 | 10 | |
| 0093-7769-24 | Everolimus | 28 in 1 CARTON | TABLET | 28 | 10 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Everolimus | EVEROLIMUS | Hikma Pharmaceuticals USA Inc. | 5aaf2fb7-93f6-40d6-941a-9583a3794ce7 | 2026-08-14 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | i3 Pharmaceuticals, LLC | be5da0fd-8fd4-4f84-a307-f270048d503c | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS TABLETS | Breckenridge Pharmaceutical, Inc. | c7bb6ba1-9a7f-43f5-b058-ef26d4b59221 | 2026-07-06 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Biocon Pharma Inc. | 5b809dfe-c076-07c5-207e-178c3f0d32d3 | 2026-06-30 | Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Teva Pharmaceuticals USA, Inc. | e3bca36b-29ed-4a2b-a1be-a57b6af805f6 | 2026-06-29 | Warnings, Adverse reactions | ANDA210050 0093-7767-24 0093-7769-24 0093-7769-19 0093-7766-24 0093-7767-19 0093-7768-24 0093-7768-19 0093-7766-19 0093-7768 0093-7767 0093-7769 0093-7766 00093776919 998189 845515 845507 1119400 0f7ea770-928b-43b2-8971-849d1d12bbc8 e3bca36b-29ed-4a2b-a1be-a57b6af805f6 9HW64Q8G6G |
| EVEROLIMUS | EVEROLIMUS | Amneal Pharmaceuticals NY LLC | 6f1ae129-c21e-4c25-84c1-a6757d9a7eb2 | 2026-06-16 | Warnings, Adverse reactions | 9HW64Q8G6G |
| TORPENZ | EVEROLIMUS | Upsher-Smith Laboratories, LLC | 4c0075dd-a0a8-4dc4-be32-1be8383fbbdc | 2026-06-10 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| Afinitor | EVEROLIMUS | Novartis Pharmaceuticals Corporation | 2150f73a-179b-4afc-b8ce-67c85cc72f04 | 2026-06-01 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| Yulithira | EVEROLIMUS | CivicaScript, LLC | 5e325efa-8ae6-4dac-b59b-d7c74c73186c | 2026-03-31 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| everolimus | EVEROLIMUS | Novugen Pharma (USA) LLC. | 67e62e26-448d-46ec-b5a1-00dc1b5e26c6 | 2026-03-10 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| everolimus | EVEROLIMUS | Aurobindo Pharma Limited | 43ef3c29-0e25-4fdd-aea1-06a20af9bbab | 2026-02-26 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Zortress | EVEROLIMUS | Novartis Pharmaceuticals Corporation | e082a024-7850-400b-a5c2-2a140612562a | 2026-02-12 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Ascend Laboratories, LLC | 2693c497-a70b-4d00-b6db-602c872e5bed | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Natco Pharma Limited | d44998bb-5deb-4ee7-a0a5-979fe3f49557 | 2025-10-14 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Breckenridge Pharmaceutical, Inc. | 01f7b5fb-be0d-4adf-acd2-6899018de966 | 2025-09-05 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Biocon Pharma Inc. | 435da284-ef0e-ca90-e0db-bab9382922e0 | 2025-05-30 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| EVEROLIMUS | EVEROLIMUS | Biocon Pharma Inc. | 5fb55800-f322-6bb6-9dde-622925ef28bd | 2025-03-21 | Warnings, Adverse reactions | 998189 845515 845507 1119400 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Par Health USA, LLC | 59cb86d5-8706-4619-b074-af253d3e0b68 | 2025-01-13 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Everolimus | EVEROLIMUS | Hikma Pharmaceuticals USA Inc. | cf2dd54b-7a1d-4401-9a01-75e68235e433 | 2024-09-03 | Boxed warning, Warnings, Adverse reactions | 9HW64Q8G6G |
| Multi-Phenolic | MANNOSE, 5-HYDROXYTRYPTOPHAN, ACETALDEHYDE, ACETYLCHOLINE CHLORIDE, ASCORBICUM ACIDUM, ASPARTAME, BUTYLATED HYDROXYTOLUENE, CAFFEIC ACID, CANDIDA ALBICANS, CINNAMIC ACID, CONIFERYL ALCOHOL, COUMARINUM, DOPAMINE HYDROCHLORIDE, ESTRADIOL, GABA (GAMMA-AMINOBUTYRIC ACID), GALLICUM ACIDUM, HISTAMINUM HYDROCHLORICUM, HYDROCORTISONE, INDOLUM, L-DOPA, L-PHENYLALANINE, MELATONIN, MENADIONE, NOREPINEPHRINE (BITARTRATE), PETROSELINUM CRISPUM, PHENYL ISOTHIOCYANATE, PIPERINE, PROGESTERONE, PYRROLE, QUERCETIN, | Energique, Inc. | 492b412a-01cc-48f2-bcdc-6fffcc651963 | 2024-08-23 | Warnings | 1P9D0Z171K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.